ClinicalTrials.gg
RecruitingNCT06638541DESTINATION 2Updated Mar 23, 2026

Dose dE-eScalaTion IN prostATe radIOtherapy usiNg an MR-Linac in 2 Fractions

An interventional study of Prostate radical radiotherapy in Prostate Cancer, sponsored by Royal Marsden NHS Foundation Trust. Recruiting at 3 sites in 2 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-23.

Sponsored by Royal Marsden NHS Foundation Trust · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Prostatic Neoplasms by Royal Marsden NHS Foundation Trust — 8 open to participants now, 10 under way, 1 of them phase 3. Prostatic Neoplasms · Royal Marsden NHS Foundation Trust.

Planned enrollment
9th of 14
54 · median 81
Started
2025
with 1 other
No phase
9 of 21
4 open now
Registered
17th of 21
by date

Among the 21 studies in Prostatic Neoplasms by Royal Marsden NHS Foundation Trust, this one is the 9th largest by planned enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2025, is one of 9 with no phase, and was the 17th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

8 of the 21 studies in Prostatic Neoplasms by Royal Marsden NHS Foundation Trust are open now, in 2 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Prostatic Neoplasms by Royal Marsden NHS Foundation Trust, or all of them as a file.
02

Study summary

DESTINATION 2 is a multi-centre randomised trial treating intermediate risk localised prostate cancer with 2 fraction Stereotactic Body Radiotherapy (SBRT). All radiotherapy will be delivered in two fractions (sessions) on an MR Linac using daily adaptation. Men will either receive uniform dose radiotherapy or de-escalated dose radiotherapy. The primary endpoint is acute GU CTCAE v5 grade 2+ toxicity. It will also look at late toxicity, patient-reported outcome measures and PSA control.

Read the detailed description

54 patients meeting inclusion criteria will be randomised between two arms. Arm 1 (Uniform dose) will receive 27 Gy in 2 fractions to the whole prostate + seminal vesicles (SV), the CTV, with 0 mm CTV-PTV margin. Arm 2 (De-escalated dose) will use two dose levels: The benign prostate (on MRI) will receive 20 Gy in 2 fractions with a 0mm PTV margin. The intraprostatic tumour mass(es) as seen on MRI will receive 27 Gy in 2 fractions. A 4mm GTV-PTV margin will be added to the MR visible tumour to form PTV 27Gy. The primary endpoint is emergent acute GU CTCAE v5 Grade 2+ toxicity, recorded within 3 months of completing radiotherapy. Secondary endpoints are CT CAE v5 acute GI toxicity, late toxicity, patient-reported outcome measures (PROMs) (EPIC-26, IPSS, and IIEF-5) at 4 and 12 weeks, 6 months, 1 and 2 years post treatment, PSA control and kinetics

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • De-escalation
  • Radiotherapy
  • MR-Linac
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men aged ≥18 years
  2. Histological confirmation of prostate adenocarcinoma requiring radical radiotherapy
  3. Gleason score 3+3, 3+4 or 4+3 (Grade groups (GG) 1, 2 or 3)
  4. MRI stage T3a or less (as staged by AJCC TNM 2018). MRI must be performed within a year of randomisation
  5. MRI-visible tumour(s) of PIRADS v2 grade 3 or higher and able to be delineated on T2 and diffusion-weighted imaging +/- dynamic contrast-enhanced imaging. Tumour nodule visible on MRI should be considered able to be boosted by treating clinician and \<2.5cm in maximal dimension
  6. The MRI-defined lesion must be confirmed as malignant on (Gleason grade must be within the limits expressed in inclusion factor 3)
  7. Patients can be concurrently treated with androgen deprivation therapy (ADT) if this would be standard of care. LHRH analogues, LHRH agonists or Bicalutamide are permitted. ADT is not mandatory where this would usually be omitted.
  8. PSA \<20 ng/ml prior to starting ADT, if used
  9. 0-2
  10. Ability of the participant understand and the willingness to sign a written form.
  11. Willing to consent to during and for 1 year after treatment when applicable.
  12. Ability/willingness to comply with the patient reported outcome questionnaires schedule throughout the study.

Exclusion criteria

Exclusion Criteria:

  1. to MRI (e.g. pacemaker, potentially mobile metal implant, claustrophobia)
  2. Severe GU symptoms that would preclude extreme hypofractionation per the discretion of the treating physician.
  3. IPSS Score > 19
  4. High grade disease (GG3) occult to MRI-defined lesion. As a guide, any pathology for which you would consider surveillance (eg GG1, low volume GG2) is allowed outside of the MRI-defined area.
  5. Prostate volume >90cc
  6. Comorbidities which predispose to significant toxicity (e.g. inflammatory bowel disease) or preclude long term follow up
  7. Hip replacement, or other pelvic metalwork which causes significant artefact on diffusion-weighted imaging
  8. Previous pelvic radiotherapy
  9. Patients needing >6 months of ADT due to disease parameters.
  10. Previous invasive within the last 2 years where this is likely to shorten lifespan the following will remain eligible: basal or squamous carcinomas of the skin, low risk non-muscle invasive bladder cancer (assuming cystoscopic follow up now negative) or small renal masses on surveillance.
  11. Participating in another interventional trial for prostate cancer
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
54 participants (estimated)

Study arms

  • Active comparator
    Uniform dose

    Arm 1 (Uniform dose) will receive 27 Gy in 2 fractions to the whole prostate + seminal vesicles (SV), the CTV, with 0 mm CTV-PTV margin.

    Radiation: Prostate radical radiotherapy

  • Experimental
    De-escalated dose

    Arm 2 (De-escalated dose) will use two dose levels: The benign prostate (on MRI) will receive 20 Gy in 2 fractions with a 0mm PTV margin. The intraprostatic tumour mass(es) as seen on MRI will receive 27 Gy in 2 fractions. A 4mm GTV-PTV margin will be added to the MR visible tumour to form PTV 27Gy.

    Radiation: Prostate radical radiotherapy

Interventions

  • RadiationProstate radical radiotherapy

    Radiation: De-escalated radiotherapy to be delivered on the Elekta Unity MR-linac

06

What researchers measure

Primary outcomes

  1. Acute GU toxicity

    To describe the absolute risk and relative risk reduction of acute genitourinary (GU) toxicity (CTCAE v5) when delivering de-escalated two fraction prostate SBRT compared to uniform dose two fraction prostate stereotactic body radiotherapy (SBRT) for intermediate risk prostate cancer.

    Time frame: 12 weeks

Secondary outcomes

  1. Acute Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0) toxicity

    To describe the absolute and relative risk of toxicity

    Time frame: Baseline, last fraction, week 2, 4 and 12

  2. Late Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0) toxicity

    To describe the absolute and relative risk of toxicity

    Time frame: Month 6, 12, 24

  3. Feasibility of radiation delivery

    Feasibility- estimate percentage of fractions interrupted due to patient discomfort

    Time frame: At time of treatment

  4. Dosimetry

    Dosimetry- estimate the accumulated dose differences between the de-escalated and uniform dose delivery

    Time frame: At time of treatment

  5. Patient reported outcome measures

    To assess baseline, acute and late International Prostate Symptom Score (IPSS). IPSS ranges from 0 to 35. Lower scores are better: A lower score indicates fewer or less severe urinary symptoms, while a higher score suggests more severe symptoms.

    Time frame: Baseline, last fraction of treatment, week 2, 4 and 12, 6 months, 1 and 2 years post treatment.

  6. Patient reported outcome measures

    Expanded Prostate Cancer Index Composite Short Form (EPIC-26). EPIC-26 scores are transformed to a 0-100 scale for each domain.The questionnaire usually covers urinary incontinence, urinary irritative/obstructive symptoms, bowel, sexual, and hormonal functions. Higher scores represent better health-related quality of life.

    Time frame: Baseline, 4 and 12 weeks, 6 months, 1 and 2 years post treatment.

  7. Patient reported outcome measures

    International Index of Erectile Function-5 (IIEF-5). The IIEF-5 score ranges from 5 to 25. Higher scores are better: A higher score indicates better erectile function, while a lower score suggests more severe erectile dysfunction.

    Time frame: Baseline, 6 months, 1 and 2 years post treatment.

  8. PSA kinetics

    To assess biochemical relapse-free survival at 2 years

    Time frame: Baseline (pre ADT), week 12, month 6, and 1 and 2 years post treatment

07

Study locations

2 of 3 sites recruiting
08

References and documents

Publications

  • Cooper S, Alexander S, Breitkreutz D, Casey F, Christodouleas J, Dassen MG, Dell'acqua V, Dunlop A, Herbert T, Kolias P, Mitchell A, Pos FJ, Westley R, Tree AC, Van Der Heide UA, Vesprini D. Dose dE-eScalaTion IN prostATe radIOtherapy usiNg an MR-Linac in 2 Fractions (DESTINATION 2): protocol for a randomised, phase II/R-IDEAL2b trial. BMJ Open. 2026 May 7;16(5):e111791. doi: 10.1136/bmjopen-2025-111791. PubMed 42097645 ↗

Individual participant data

Plan to share: Yes — It is intended that data will be shared within the MOMENTUM collaboration, between centres delivering treatment in the same way as DESTINATION2. Pseudonymised data will be stored within MOMENTUM for at least 5 years. Storage will be cloud based and as the treating centre we will have free access to the data and control over who else can assess it.

Time frame: 5 years

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Jan 2027, 23 months after the start.

Of 1,104 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's planned 23 months is below that.

Counting every sponsor, half of 1,162 studies reached it within 43 months; a quarter within 22 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2024
First posted
Oct 15, 2024
StartActual
Jan 20, 2025
Primary completionEst.
Jan 1, 2027
CompletionEst.
Jan 1, 2027
Last update
Mar 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06638541
Collaborators
Elekta Limited, MRL Consortium
Responsible party
Sponsor
First posted
Oct 15, 2024
Start date
Jan 20, 2025
Primary completion
Jan 1, 2027 (estimated)
Completion
Jan 1, 2027 (estimated)
Last update
Mar 23, 2026

Study contacts

Francesca Mason
Contact
mrltrials@rmh.nhs.uk
+44 20 3186 5157
Sian Cooper
Contact
sian.cooper@rmh.nhs.uk
Alison Tree
study chair · Royal Marsden Hospital, Institute of Cancer Research

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion